HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Metformin and thiazolidinedione use in Medicare patients with heart failure.

AbstractCONTEXT:
According to package inserts, metformin is contraindicated in diabetic patients receiving drug treatment for heart failure therapy, and thiazolidinediones are not recommended in diabetic patients with symptoms of advanced heart failure. Little is known about patterns of use of these antihyperglycemic drugs in diabetic patients with heart failure.
OBJECTIVE:
To determine the proportions of patients hospitalized with heart failure and concomitant diabetes treated with metformin or thiazolidinediones.
DESIGN:
Serial cross-sectional measurements using data from retrospective medical record abstraction.
SETTING:
Nongovernmental acute care hospitals in the United States.
PATIENTS:
Two nationally representative samples of Medicare beneficiaries hospitalized with the primary diagnosis of heart failure and concomitant diabetes between April 1998 and March 1999 and between July 2000 and June 2001.
MAIN OUTCOME MEASURES:
The prescription of either metformin or a thiazolidinedione at hospital discharge.
RESULTS:
In the 1998-1999 sample (n = 12 505), 7.1% of patients were discharged with a prescription for metformin, 7.2% with a prescription for a thiazolidinedione, and 13.5% with a prescription for either drug. In the 2000-2001 sample (n = 13 158), metformin use increased to 11.2%, thiazolidinedione use to 16.1%, and use of either drug to 24.4% (P<.001 for all comparisons). Similar increases were seen among patients of all age groups, all races, and both sexes.
CONCLUSIONS:
The use of metformin and thiazolidinediones is common and has increased rapidly in Medicare beneficiaries with diabetes and heart failure in direct contrast with explicit warnings against this practice by the Food and Drug Administration. Further studies to establish the safety and effectiveness of this practice are needed to ensure optimal care of patients with diabetes and heart failure.
AuthorsFrederick A Masoudi, Yongfei Wang, Silvio E Inzucchi, John F Setaro, Edward P Havranek, JoAnne M Foody, Harlan M Krumholz
JournalJAMA (JAMA) Vol. 290 Issue 1 Pg. 81-5 (Jul 02 2003) ISSN: 1538-3598 [Electronic] United States
PMID12837715 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Cardiotonic Agents
  • Hypoglycemic Agents
  • Thiazoles
  • Thiazolidinediones
  • Metformin
  • 2,4-thiazolidinedione
Topics
  • Aged
  • Aged, 80 and over
  • Cardiotonic Agents (therapeutic use)
  • Contraindications
  • Cross-Sectional Studies
  • Diabetes Complications
  • Diabetes Mellitus (drug therapy)
  • Drug Utilization Review
  • Female
  • Heart Failure (complications, drug therapy)
  • Hospitalization
  • Humans
  • Hypoglycemic Agents (therapeutic use)
  • Male
  • Medicare
  • Metformin (therapeutic use)
  • Retrospective Studies
  • Thiazoles (therapeutic use)
  • Thiazolidinediones
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: